These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 18227733)
21. Survivin expression in colorectal adenocarcinoma using tissue microarray. Abd El-Hameed A J Egypt Natl Canc Inst; 2005 Mar; 17(1):42-50. PubMed ID: 16353082 [TBL] [Abstract][Full Text] [Related]
22. Survivin expression predicts early recurrence in early-stage breast cancer. Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451 [TBL] [Abstract][Full Text] [Related]
23. Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer. Yakirevich E; Samkari A; Holloway MP; Lu S; Singh K; Yu J; Fenton MA; Altura RA Hum Pathol; 2012 Jun; 43(6):865-73. PubMed ID: 22055399 [TBL] [Abstract][Full Text] [Related]
24. Expression of survivin, caspase-3 and p53 in cervical cancer assessed by tissue microarray: correlation with clinicopathology and prognosis. Lu H; Gan M; Zhang G; Zhou T; Yan M; Wang S Eur J Gynaecol Oncol; 2010; 31(6):662-6. PubMed ID: 21319512 [TBL] [Abstract][Full Text] [Related]
25. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Cohen C; Lohmann CM; Cotsonis G; Lawson D; Santoianni R Mod Pathol; 2003 Jun; 16(6):574-83. PubMed ID: 12808063 [TBL] [Abstract][Full Text] [Related]
26. Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. Kostadima L; Pentheroudakis G; Fountzilas G; Dimopoulos M; Pectasides D; Gogas H; Stropp U; Christodoulou C; Samantas E; Wirtz R; Hennig G; Bafaloukos D; Arapantoni P; Kalofonos H; Papakostas P; Economopoulos T; Bamias A; Pavlidis N Breast Cancer Res Treat; 2006 Nov; 100(2):161-7. PubMed ID: 16823513 [TBL] [Abstract][Full Text] [Related]
27. Survivin expression correlates with unfavourable prognoses in invasive ductal carcinoma of the breast. Al-Joudi FS; Iskandar ZA; Imran AK Med J Malaysia; 2007 Mar; 62(1):6-8. PubMed ID: 17682561 [TBL] [Abstract][Full Text] [Related]
28. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Brennan DJ; Rexhepaj E; O'Brien SL; McSherry E; O'Connor DP; Fagan A; Culhane AC; Higgins DG; Jirstrom K; Millikan RC; Landberg G; Duffy MJ; Hewitt SM; Gallagher WM Clin Cancer Res; 2008 May; 14(9):2681-9. PubMed ID: 18451232 [TBL] [Abstract][Full Text] [Related]
29. Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Singh M; Bleile MJ; Shroyer AL; Heinz D; Jarboe EA; Shroyer KR Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):296-304. PubMed ID: 15536328 [TBL] [Abstract][Full Text] [Related]
30. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma. Xiang Y; Yao H; Wang S; Hong M; He J; Cao S; Min H; Song E; Guo X Laryngoscope; 2006 Jan; 116(1):126-30. PubMed ID: 16481824 [TBL] [Abstract][Full Text] [Related]
31. [Research advances on inhibitor of apoptosis, survivin]. Yang J; Liu FX; Yan XC Ai Zheng; 2003 Jul; 22(7):771-4. PubMed ID: 12866973 [TBL] [Abstract][Full Text] [Related]
32. The role of survivin as a new target of diagnosis and treatment in human cancer. Yamamoto T; Tanigawa N Med Electron Microsc; 2001 Dec; 34(4):207-12. PubMed ID: 11956993 [TBL] [Abstract][Full Text] [Related]
33. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523 [TBL] [Abstract][Full Text] [Related]
34. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Tanaka K; Iwamoto S; Gon G; Nohara T; Iwamoto M; Tanigawa N Clin Cancer Res; 2000 Jan; 6(1):127-34. PubMed ID: 10656440 [TBL] [Abstract][Full Text] [Related]
35. [Expression of survivin in different stages of carcinogenesis and progression of breast cancer]. Zhang SQ; Qiang SY; Yang WB; Jiang JT; Ji ZZ Ai Zheng; 2004 Jun; 23(6):697-700. PubMed ID: 15191674 [TBL] [Abstract][Full Text] [Related]
36. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Offersen BV; Alsner J; Ege Olsen K; Riisbro R; Brünner N; Sørensen FB; Sørensen BS; Schlemmer BO; Overgaard J Acta Oncol; 2008; 47(4):618-32. PubMed ID: 18465330 [TBL] [Abstract][Full Text] [Related]
37. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH Oncology; 2004; 66(6):429-38. PubMed ID: 15452371 [TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. Uematsu M; Ohsawa I; Aokage T; Nishimaki K; Matsumoto K; Takahashi H; Asoh S; Teramoto A; Ohta S J Neurooncol; 2005 May; 72(3):231-8. PubMed ID: 15937645 [TBL] [Abstract][Full Text] [Related]
39. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2. Mainou-Fowler T; Overman LM; Dignum H; Wood K; Crosier S; Angus B; Proctor SJ; Anderson JJ Int J Oncol; 2008 Jan; 32(1):59-68. PubMed ID: 18097543 [TBL] [Abstract][Full Text] [Related]